secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073391
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian reports 2025 net loss of $342.6M; veligrotug PDUFA date June 30, 2026
------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities were $874.7M as of Dec 31, 2025, up from $717.6M.
- Net loss for 2025 was $342.6M ($269.9M in 2024); R&D spend rose to $338.9M.
- PDUFA target action date for veligrotug BLA is June 30, 2026; Priority Review ongoing.
- MAA for veligrotug submitted to EMA in January 2026 for European approval.
- Phase 3 REVEAL-1 topline data for elegrobart on track for Q1 2026; REVEAL-2 for Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/0001193125-26-073391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/d105707d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer